OncoMatch/Clinical Trials/NCT07193966
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Is NCT07193966 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies NG2 and DLL3 CAR-T cells for melanoma.
Treatment: NG2 and DLL3 CAR-T cells — The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Required: CSPG4 positive expression (positive)
Required: DLL3 positive expression (positive)
Disease stage
Metastatic disease required
Prior therapy
Must have received: standard first-line therapy
Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions.
Cannot have received: genetically engineered CAR T cells
Previous treatment with other genetically engineered CAR T cells.
Lab requirements
Blood counts
WBC ≥1000/ul, ANC ≥500/ul, ALC ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion)
Kidney function
serum creatinine less than 3 times ULN
Liver function
ALT <3x ULN, AST <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN
Cardiac function
Left ventricular ejection fraction ≥40/55 percent
Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN. Renal function: Patients must have serum creatinine less than 3 times ULN. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion). Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent. Pulse Ox greater than or equal to 90% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify